By Fineline Cube China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I clinical study of its GT20029, targeting androgenetic alopecia and acne. The study, which enrolled 120 subjects in the US, is a randomized, double-blind, placebo-controlled, parallel, dosage escalation trial designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy subjects via single doses and in subjects with androgenetic alopecia or acne via multiple doses.
GT20029: Drug Profile and Mechanism
GT20029 is described as the world’s first external-use compound based on proteolytic targeting chimera (PROTAC) technology. The drug targets the androgen receptor (AR) pathway, which is a key factor in the pathogenesis of androgenetic alopecia and acne. GT20029 works by degrading the androgen receptor protein, effectively blocking the AR signaling pathway and its physiological functions. This mechanism allows the drug to exert local therapeutic effects while reducing systemic drug exposure and avoiding the side effects associated with oral treatments.
Clinical Progress and Future Outlook
Kintor previously obtained clinical study approval for GT20029 in the US and China. In August of this year, all subjects were dosed in a Phase I study for androgenetic alopecia and acne. With the completion of enrollment in the US, Kintor is poised to advance GT20029 through clinical development, aiming to address the significant unmet needs in the treatment of these conditions.-Fineline Info & Tech